Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

View Full Paper
Ask AI
Bookmark
Share

Authors

BDBenjamin DiamondMKMarcella KaddouraKKK Koubek

Discussion

Loading...

Member takes

Overview

Analysis shows disease burden monitoring via next-generation sequencing in blood reveals challenges for MRD assessment in multiple myeloma.

Key Points

  • To compare disease burden in bone marrow and peripheral blood in newly diagnosed multiple myeloma patients after frontline therapy.
  • Participants received carfilzomib-lenalidomide-dexamethasone with or without daratumumab.
  • Samples were analyzed for disease burden by next-generation sequencing at 10-6 sensitivity.
  • Comparisons of clonotypic sequences were made between bone marrow and peripheral blood.
  • At baseline, all samples were MRD positive by clonoSEQ.
  • Bone marrow disease burden was higher than peripheral blood by 2.54 log differences on average.
  • After treatment, 82% of peripheral blood samples were MRD negative compared to 31% for bone marrow.

Cite This Study

Diamond et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e22fhttps://doi.org/10.1182/blood-2025-7454
View Full Paper
Ask AI
Bookmark
Share